JP2015535816A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535816A5
JP2015535816A5 JP2015532065A JP2015532065A JP2015535816A5 JP 2015535816 A5 JP2015535816 A5 JP 2015535816A5 JP 2015532065 A JP2015532065 A JP 2015532065A JP 2015532065 A JP2015532065 A JP 2015532065A JP 2015535816 A5 JP2015535816 A5 JP 2015535816A5
Authority
JP
Japan
Prior art keywords
ala
ile
leu
val
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015532065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535816A (ja
JP6461796B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/059608 external-priority patent/WO2014043441A1/en
Publication of JP2015535816A publication Critical patent/JP2015535816A/ja
Publication of JP2015535816A5 publication Critical patent/JP2015535816A5/ja
Application granted granted Critical
Publication of JP6461796B2 publication Critical patent/JP6461796B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015532065A 2012-09-14 2013-09-13 Mhcクラスii拘束性mage−a3を認識するt細胞受容体 Active JP6461796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701056P 2012-09-14 2012-09-14
US61/701,056 2012-09-14
PCT/US2013/059608 WO2014043441A1 (en) 2012-09-14 2013-09-13 T cell receptors recognizing mhc class ii-restricted mage-a3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018243703A Division JP6728326B2 (ja) 2012-09-14 2018-12-26 Mhcクラスii拘束性mage−a3を認識するt細胞受容体

Publications (3)

Publication Number Publication Date
JP2015535816A JP2015535816A (ja) 2015-12-17
JP2015535816A5 true JP2015535816A5 (enExample) 2016-11-04
JP6461796B2 JP6461796B2 (ja) 2019-01-30

Family

ID=49253425

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015532065A Active JP6461796B2 (ja) 2012-09-14 2013-09-13 Mhcクラスii拘束性mage−a3を認識するt細胞受容体
JP2018243703A Active JP6728326B2 (ja) 2012-09-14 2018-12-26 Mhcクラスii拘束性mage−a3を認識するt細胞受容体
JP2020114090A Active JP6923714B2 (ja) 2012-09-14 2020-07-01 Mhcクラスii拘束性mage−a3を認識するt細胞受容体
JP2021124003A Active JP7270001B2 (ja) 2012-09-14 2021-07-29 Mhcクラスii拘束性mage-a3を認識するt細胞受容体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018243703A Active JP6728326B2 (ja) 2012-09-14 2018-12-26 Mhcクラスii拘束性mage−a3を認識するt細胞受容体
JP2020114090A Active JP6923714B2 (ja) 2012-09-14 2020-07-01 Mhcクラスii拘束性mage−a3を認識するt細胞受容体
JP2021124003A Active JP7270001B2 (ja) 2012-09-14 2021-07-29 Mhcクラスii拘束性mage-a3を認識するt細胞受容体

Country Status (20)

Country Link
US (4) US9879065B2 (enExample)
EP (3) EP4159753A1 (enExample)
JP (4) JP6461796B2 (enExample)
KR (4) KR102165350B1 (enExample)
CN (2) CN104968675B (enExample)
AU (4) AU2013315391B2 (enExample)
CA (1) CA2884743C (enExample)
CY (1) CY1122720T1 (enExample)
DK (2) DK2895509T3 (enExample)
ES (2) ES2925307T3 (enExample)
HR (1) HRP20200325T1 (enExample)
HU (1) HUE048014T2 (enExample)
IL (3) IL286786B (enExample)
LT (1) LT2895509T (enExample)
MX (2) MX367279B (enExample)
PL (1) PL2895509T3 (enExample)
PT (1) PT2895509T (enExample)
SI (1) SI2895509T1 (enExample)
SM (1) SMT202000103T1 (enExample)
WO (1) WO2014043441A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2895509T3 (da) * 2012-09-14 2020-03-09 Us Health T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
FI3273986T3 (fi) * 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
US11208468B2 (en) 2016-02-18 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
PL3430037T3 (pl) * 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018097951A1 (en) 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术(广东)有限公司 源自于mage b6的肿瘤抗原短肽
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
CA3077595A1 (en) * 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
WO2019075055A1 (en) 2017-10-11 2019-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN109837248A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
CN109836490A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
EP3740198A4 (en) 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center MODIFICATION OF INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATION OF CELL ACTIVATION STATES
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN118374524A (zh) 2018-02-09 2024-07-23 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
JP7469807B2 (ja) * 2018-04-19 2024-04-17 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Mage-b2特異性を有するt細胞受容体およびその使用
CN112262212B (zh) 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
MX2021013588A (es) 2019-05-08 2022-02-11 Medigene Immunotherapies Gmbh Células t genomodificadas.
MX2022000667A (es) * 2019-07-15 2022-07-21 Neogene Therapeutics B V Metodo para aislar genes tcr.
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞受容体を単離する方法
AU2021341969A1 (en) 2020-09-08 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN119156224A (zh) 2021-12-31 2024-12-17 美国政府(由卫生和人类服务部的部长所代表) 接种疫苗的t细胞疗法作为针对癌症的联合免疫疗法
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CN103097407A (zh) * 2010-07-28 2013-05-08 英美偌科有限公司 T细胞受体
AU2011304728A1 (en) * 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
CA3114877C (en) 2011-09-15 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
US9413985B2 (en) * 2012-09-12 2016-08-09 Lattice Semiconductor Corporation Combining video and audio streams utilizing pixel repetition bandwidth
DK2895509T3 (da) * 2012-09-14 2020-03-09 Us Health T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3

Similar Documents

Publication Publication Date Title
HRP20200325T1 (hr) T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3
CN112300269B (zh) Kras突变特异性t细胞受体筛选及抗肿瘤用途
JP2015525208A5 (enExample)
TWI880898B (zh) 單鏈嵌合多肽及其用途
US10538573B2 (en) Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
JP2018535647A5 (enExample)
JP2020534828A5 (enExample)
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
FI3688027T3 (fi) Mutatoidun p53:n tunnistavia t-solureseptoreita
IL301894B1 (en) Anti-kras-g12d t cell receptors
JP2014528714A5 (enExample)
IL275497B (en) Serum proteins with type iii fibronectin binding domains
WO2020082130A1 (en) T-cell receptors and uses thereof
JP2017536825A5 (enExample)
WO2009042570A3 (en) Modified t cell receptors and related materials and methods
RU2016124670A (ru) Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
Xu et al. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
CA2967778A1 (en) Anti-thyroglobulin t cell receptors
CN108779164A (zh) Hla-b57开放型构象异构体
JP2017536821A5 (enExample)
CN101565455B (zh) 禽流感h5n1病毒的ctl表位多肽及其应用
He et al. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice
Low et al. Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes
RU2013115434A (ru) Пептиды ttll4 и содержащие их вакцины